GI Innovation, Inc. (KOSDAQ:358570)

Market Cap	844.05B +22.7%
Revenue (ttm)	5.84B +23,943.4%
Net Income	-35.13B
EPS	-604.00
Shares Out	64.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,139
Average Volume	660,809
Open	13,250
Previous Close	13,170
Day's Range	13,040 - 14,100
52-Week Range	11,290 - 24,900
Beta	0.60
RSI	51.44
Earnings Date	n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 358570

Financial Performance

In 2025, GI Innovation's revenue was 5.84 billion, an increase of 23943.39% compared to the previous year's 24.28 million. Losses were -35.13 billion, -40.23% less than in 2024.